Skip to main content
    M

    Medpace Holdings Inc (MEDP)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $648.20
    -5.74 (-0.88%)

    Market Cap: $18.29B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Medpace Holdings Inc (MEDP) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Medpace Holdings (MEDP) trades at 35.9x trailing earnings and 6.4x sales. Its P/E of 35.9x is above its 5-year median of 30.1x. Its forward P/E is 33.1x. The median P/E across 11 similar companies is 26.8x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 8.5% higher over the next year. Its free cash flow yield is 3.7%.

    MultipleValue
    P/E (trailing)35.9x
    Forward P/E33.1x
    Price to sales6.4x
    Price to book31.0x
    EV/EBITDA27.4x
    Price to FCF27.1x
    EV/FCF26.1x
    PEG3.4
    FCF yield3.7%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 24.2% above 28.9x, its P/S is 42.2% above 4.5x and its P/B is 307.9% above 7.6x.

    MultipleCurrent5-year median10-year median
    P/E35.9x30.1x28.9x
    P/S6.4x5.0x4.5x
    P/B31.0x17.8x7.6x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 116 to 120 months (10-year).

    Valuation History

    Over the 9 of the 10 year ends shown that have a P/E, its P/E ranged from 20.4x in 2018 to 44.3x in 2021.

    Year endPriceP/EP/SP/B
    2025$561.6536.7x6.4x35.4x
    2024$332.2326.2x4.9x12.9x
    2023$306.5334.3x5.0x17.5x
    2022$212.4128.8x4.7x17.8x
    2021$217.6444.3x6.9x8.6x
    2020$139.2035.1x5.4x6.5x
    2019$84.0627.9x3.6x4.4x
    2018$52.9320.4x2.7x3.3x
    2017$36.2624.0x3.3x2.7x
    2016$36.07N/A3.4x2.4x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About MEDP

    What is MEDP's forward P/E ratio?

    Medpace Holdings has a forward P/E ratio of 33.1x.

    Is MEDP stock overvalued?

    GNG's valuation label for MEDP is Overvalued. Its P/E of 35.9x compares with a median of 26.8x across 11 similar companies.

    What is MEDP's price to sales ratio?

    Medpace Holdings has a price to sales ratio of 6.4x.

    What is Medpace Holdings's average P/E ratio over 5 years?

    Medpace Holdings's median P/E over the last 5 years is 30.1x, from 60 month-end values through Oct 2026.

    What is MEDP's PEG ratio?

    Medpace Holdings has a PEG ratio of 3.4.